Thus, a previous report showed that anti-TIM3 treatment of tumors in combination with anti-PD-L1 is more effective in controlling tumor growth when compared to treatment with anti-PD-L1 antibodies alone [32]. The gene discussed is CD274; the disease is neoplasm.